Compare VENUS REMEDIES with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PIRAMAL ENTERPRISES VENUS REMEDIES/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -1.0 18.4 - View Chart
P/BV x 0.1 1.2 6.2% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 VENUS REMEDIES   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
PIRAMAL ENTERPRISES
Mar-19
VENUS REMEDIES/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1263,303 3.8%   
Low Rs611,797 3.4%   
Sales per share (Unadj.) Rs301.8716.5 42.1%  
Earnings per share (Unadj.) Rs-24.979.7 -31.2%  
Cash flow per share (Unadj.) Rs2.5107.9 2.4%  
Dividends per share (Unadj.) Rs028.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs293.31,477.5 19.8%  
Shares outstanding (eoy) m12.34184.45 6.7%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.33.6 8.7%   
Avg P/E ratio x-3.832.0 -11.8%  
P/CF ratio (eoy) x36.723.6 155.5%  
Price / Book Value ratio x0.31.7 18.5%  
Dividend payout %035.1 0.0%   
Avg Mkt Cap Rs m1,154470,292 0.2%   
No. of employees `0000.97.8 11.8%   
Total wages/salary Rs m39322,504 1.7%   
Avg. sales/employee Rs Th4,026.116,899.4 23.8%   
Avg. wages/employee Rs Th425.02,877.7 14.8%   
Avg. net profit/employee Rs Th-331.81,879.9 -17.6%   
INCOME DATA
Net Sales Rs m3,724132,153 2.8%  
Other income Rs m233,128 0.7%   
Total revenues Rs m3,747135,281 2.8%   
Gross profit Rs m39566,290 0.6%  
Depreciation Rs m3385,202 6.5%   
Interest Rs m35444,097 0.8%   
Profit before tax Rs m-27520,119 -1.4%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m328,611 0.4%   
Profit after tax Rs m-30714,701 -2.1%  
Gross profit margin %10.650.2 21.1%  
Effective tax rate %-11.542.8 -26.8%   
Net profit margin %-8.211.1 -74.1%  
BALANCE SHEET DATA
Current assets Rs m2,638122,742 2.1%   
Current liabilities Rs m2,305310,810 0.7%   
Net working cap to sales %8.9-142.3 -6.3%  
Current ratio x1.10.4 289.8%  
Inventory Days Days13523 587.1%  
Debtors Days Days4639 119.3%  
Net fixed assets Rs m4,871116,904 4.2%   
Share capital Rs m123369 33.5%   
"Free" reserves Rs m3,496272,161 1.3%   
Net worth Rs m3,619272,530 1.3%   
Long term debt Rs m1,374270,196 0.5%   
Total assets Rs m7,509856,261 0.9%  
Interest coverage x0.21.5 15.3%   
Debt to equity ratio x0.41.0 38.3%  
Sales to assets ratio x0.50.2 321.4%   
Return on assets %0.66.9 9.2%  
Return on equity %-8.55.4 -157.2%  
Return on capital %1.612.4 12.7%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m015,200 0.0%   
Fx outflow Rs m5174,889 10.6%   
Net fx Rs m-51710,312 -5.0%   
CASH FLOW
From Operations Rs m514-115,975 -0.4%  
From Investments Rs m-123-8,265 1.5%  
From Financial Activity Rs m-387107,525 -0.4%  
Net Cashflow Rs m4-16,650 -0.0%  

Share Holding

Indian Promoters % 32.9 52.9 62.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 4.0 4.5%  
FIIs % 0.6 26.6 2.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 16.5 402.4%  
Shareholders   20,121 93,274 21.6%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  UNICHEM LAB  WYETH LTD  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms Over 1,900 Points after Government Slashes Corporate Tax Rates(12:30 pm)

Share markets in India jumped sharply after FM Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 20, 2019 03:35 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS